Hikma Pharmaceutic (OTC:HKMPF) was downgraded by research analysts at HSBC Holdings plc from a “hold” rating to a “reduce” rating in a research note issued to investors on Friday, StockTargetPrices.com reports.
Hikma Pharmaceutic (OTC:HKMPF) opened at 26.50 on Friday. Hikma Pharmaceutic has a 52-week low of $20.43 and a 52-week high of $35.25. The firm’s 50-day moving average price is $25.26 and its 200 day moving average price is $24.41. The firm has a market cap of $5.99 billion and a PE ratio of 32.40.
var userip;Your IP Address: document.write(userip);
Receive News & Ratings for Hikma Pharmaceutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceutic and related companies with MarketBeat.com's FREE daily email newsletter.